Analyst Upgrades: Facebook, Cyberark Software, bluebird bio

Analysts upwardly revised their ratings on Facebook Inc (FB), Cyberark Software Ltd (CYBR), and bluebird bio Inc (BLUE)

Mar 23, 2015 at 9:25 AM
facebook X logo linkedin


Analysts are weighing in today on social network giant Facebook Inc (NASDAQ:FB), cybersecurity firm Cyberark Software Ltd (NASDAQ:CYBR), and drugmaker bluebird bio Inc (NASDAQ:BLUE). Here's a quick roundup of today's bullish brokerage notes on FB, CYBR, and BLUE.

  • It's been a record-setting run for FB of late, and the equity looks ready to extend this momentum today, after receiving price-target hikes from JMP Securities (by $3 to $97) and Piper Jaffray (by $8 to $92) -- both in territory yet to be charted. Longer term, shares of FB are up roughly 25% year-over-year, and closed Friday at $83.80. Options traders, meanwhile, have shown a distinct preference for calls over puts in recent months. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), Facebook Inc's 50-day call/put volume ratio of 2.57 ranks in the 90th annual percentile.

  • CYBR is 3.8% higher in electronic trading, thanks to an upbeat "buy" initiation from BofA-Merrill Lynch, and $60 price target -- representing expected upside of 23.2% to Friday's settlement at $48.69. This optimism shouldn't be too surprising, considering the stock has tacked on almost 23% year-to-date, but isn't shared throughout the brokerage bunch. Specifically, five out of seven analysts maintain a "hold" or worse recommendation on Cyberark Software Ltd, while the average 12-month price target of $46.88 stands at a discount to current trading levels.

  • BLUE has put in a tremendous showing on the charts, surging nearly fivefold over the past 52 weeks to trade at $124.76. Roth Capital thinks there's more room to run, and upped its price target on the stock to $145 from $120 -- in record-high waters. Elsewhere on the Street, however, skepticism has been growing. At the ISE, CBOE, and PHLX, BLUE's 10-day put/call volume ratio of 1.94 indicates nearly two puts have been bought to open for every call over the last two weeks. Plus, short interest jumped 10.9% in the last two reporting periods, and now accounts for a healthy 7.7% of the stock's available float. In fact, it would take more than a week to cover these shorted shares, at average daily trading levels. Should bluebird bio Inc continue its upward trajectory, a capitulation of some of the weaker bearish hands could translate into a fresh burst of buying power for BLUE.
 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI